Effectiveness of pneumococcal conjugate vaccines of different valences against invasive pneumococcal disease among children in Taiwan: A nationwide study

Pediatric Infectious Disease Journal

Volumn 35, Issue 4, 2016, Pages e124-e133

  Su, Wei Ju ^a,b,c   Lo, Hsiu Yun ^a   Chang, Chia Hsuin ^b,c   Chang, Luan Yin ^c   Chiu, Cheng Hsun ^d   Lee, Ping Ing ^c   Lu, Chun Yi ^c   Hsieh, Yu Chia ^d   Lai, Mei Shu ^b   Lin, Tzou Yien ^d,e  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e Ministry of Health and Welfare   (Taiwan)

Author keywords

Invasive pneumococcal disease; Invasive pneumococcal disease surveillance; Matched case control studies; Pneumococcal conjugate vaccine; Vaccine effectiveness

Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CROSS PROTECTION; DATA BASE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REGISTER; SEROTYPE; TAIWAN; VACCINATION; CLASSIFICATION; FACTUAL DATABASE; HEALTH SURVEY; IMMUNIZATION; IMMUNOLOGY; INFANT; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; TAIWAN; VACCINES, CONJUGATE;

EID: 84961958115     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001054     Document Type: Article

References (48)

1. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev Vaccines. 2008;7:1367-1394.
2. Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32:3452-3459.
3. Ben-Shimol S, Greenberg D, Givon-Lavi N, et al; Israeli Bacteremia and Meningitis Active Surveillance Group. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012;30:6600-6607.
4. Chiang CS, Chen YY, Jiang SF, et al. National surveillance of invasive pneumococcal diseases in Taiwan, 2008-2012: differential temporal emergence of serotype 19A. Vaccine. 2014;32:3345-3349.
5. Taiwan Centers for Disease Control. Weekly Invasive Pneumococcal Disease Surveillance Report; December 5, 2014. Available at: http://www. cdc.gov.tw/professional/list.aspx?treeid=098f3bc4756f62cc&nowtreeid=90 960C331E13A586. Accessed December 8, 2014.
6. Wei SH, Chiang CS, Chiu CH, et al. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:e71-e77..
7. Taiwan Centers for Disease Control. Pneumococcal conjugate vaccination program for children; December 29, 2014. Available at: http://www.cdc.gov. tw/professional/list.aspx?treeid=5B0231BEB94EDFFC&nowtreeid=B1BA 135D5CA30039. Accessed June 18, 2015.
8. Domingues CM, Verani JR, Montenegro Renoiner EI, et al; Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464-471.
9. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066-1073.
10. Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14:839-846.
11. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality. Clin Infect Dis. 2014;59:1066-1073.
12. De Wals P, Lefebvre B, Defay F, et al. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine. 2012;30:6416-6420.
13. Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33:2684-2689.
14. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
15. Madhi SA, Klugman KP, Kuwanda L, et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIVinfected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009;199:1168-1176.
16. Ekström N, Ahman H, Palmu A, et al; FinOM Study Group. Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy. Clin Vaccine Immunol. 2013;20:1034-1040.
17. Tsou TP, Liu CC, Huang JJ, et al. Change in hepatitis A epidemiology after vaccinating high risk children in Taiwan, 1995-2008. Vaccine. 2011;29:2956-2961.
18. Taiwan CDC. 2014 13-valent pneumococcal conjugate vaccine catch-up Taiwan Centers for Disease Control. 2014 13-valent pneumococcal conjugate vaccine catch-up immunization program for children aged 1-5 years; November 5, 2014. Available at: http://www.cdc.gov.tw/professional/info. aspx?treeid=5B0231BEB94EDFFC&nowtreeid=18289B1BCF6AAE46&ti d=9FF1B71EA1369E22. Accessed June 18, 2015.
19. New Jersey Department of Health and Senior Services. Age-appropriate vaccinations for licensed child care centers/pre-schools; 2014.
20. Park SY, Van Beneden CA, Pilishvili T, et al; Active Bacterial Core surveillance team. Invasive pneumococcal infections among vaccinated children in the United States. J Pediatr. 2010;156:478-483.e2.
21. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232-6238.
22. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 2007;25:2194-2212.
23. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535-543.
24. Griffin MR, Grijalva CG. Restraining the pneumococcus. Lancet Infect Dis. 2015;15:491-492.
25. Publication WHO. Pneumococcal vaccines WHO position paper - 2012-recommendations. Vaccine. 2012;30:4717-4718.
26. van der Linden M, Reinert RR, Kern WV, et al. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis. 2013;13:70.
27. Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21:3265-3272.
28. De Wals P, Lefebvre B, Markowski F, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2014;32:1501-1506.
29. Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis. 2004;190:1-10.
30. Verhaegen J, Flamaing J, De Backer W, et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011. Euro Surveill. 2014;19:14-22.
31. Le Meur JB, Lefebvre B, Proulx JF, et al. Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010. Int J Circumpolar Health. 2014;73:22691.
32. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760-768.
33. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 2010;10:4.
34. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(4 suppl):S66-S76.
35. Ramos V, Parra EL, Duarte C, et al. Response to letter by Moreira et al., regarding "PHiD-CV effectiveness against invasive pneumococcal disease caused by serotype 19A: further evidence in Colombia". Vaccine. 2015;33:416.
36. Clarke CJ, Hausdorff WP. Further evidence for the effectiveness of PCV10 against Streptococcus pneumoniae serotype 19A. Lancet Respir Med. 2014;2:e7.
37. Rodgers G. Prevention of invasive pneumococcal disease: new evidence. Lancet Respir Med. 2014;2:432-434.
38. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
39. Moreira M, Guevara JN, Caceres D. PHiD-CV effectiveness against invasive pneumococcal disease caused by serotype 19A. Vaccine. 2015;33:415.
40. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/ Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
41. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-1354.
42. Pelton SI, Weycker D, Farkouh RA, et al. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59:615-623.
43. Yildirim I, Shea KM, Little BA, et al; Members of the Massachusetts Department of Public Health. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics. 2015;135:495-503.
44. Ladhani SN, Slack MP, Andrews NJ, et al. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis. 2013;19:61-68.
45. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65:17-24.
46. Rückinger S, Dagan R, Albers L, et al. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine. 2011;29:9600-9606.
47. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr. 2002;161 (Suppl 2):S127-S131.
48. Martinelli D, Pedalino B, Cappelli MG, et al; Apulian Group for the surveillance of pediatric IPD. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013. Hum Vaccin Immunother. 2014;10:33-39.